Masters of Longevity - The Pulse

Fight Aging!23 Oct 2026
AIThe APOEε4 Variant Interferes in Myelination in the Aging Brain (Fight Aging!)

The APOEε4 Variant Interferes in Myelination in the Aging Brain

APOE4 reduced Wnt–beta‑catenin signaling in oligodendrocytes, causing lipid droplets and impaired myelination in cell and mouse models.

Key takeaways
  • APOE4 oligodendrocytes showed reduced beta‑catenin and higher GSK3b levels.
  • GSK3b inhibition restored Wnt signaling and increased myelination in models.
  • Lipid droplets accumulated in oligodendrocytes when Wnt signaling was depressed.
MoL Event Pick
HealthSpan Festival 2027 (Valencia, Spain)

HealthSpan Festival 2027

6. OCT 2027 - 7. OCT 2027 - Valencia, SpainFestival

Application-reviewed healthspan festival in Valencia on longevity science, prevention, healthcare delivery and the economics of ageing.

Longevity Technology23 Oct 2026
AIImmunis wins grand prize for novel anti-aging stem cell therapy (Longevity Technology)

Immunis wins grand prize for novel anti-aging stem cell therapy

Immunis won the National Academy of Medicine Grand Prize for IMM01-STEM, a stem-cell biologic with early reported benefits.

Key takeaways
  • IMM01-STEM is an investigational biologic targeting muscle and metabolism.
  • Early human trials reported functional and metabolic improvements.
  • These preliminary findings require follow-up and remain unconfirmed.
Science Daily - Health & Medicine23 Oct 2026
Scientists discover a surprising double benefit of exercise for Parkinson’s (Science Daily - Health & Medicine)

Scientists discover a surprising double benefit of exercise for Parkinson’s

An observational cohort found greater baseline activity tied to slower motor and cognitive progression over seven years.

Key takeaways
  • Greater baseline activity was linked to slower motor decline.
  • Greater baseline activity was linked to slower cognitive decline.
  • These observational results are not proof of cause and effect.
Longevity Technology23 Oct 2026
AICognition Therapeutics gets FDA alignment for Phase 3 Zervimesine trial (Longevity Technology)

Cognition Therapeutics gets FDA alignment for Phase 3 Zervimesine trial

FDA and Cognition Therapeutics agreed Phase 3 CT1812 endpoints for DLB patients.

Key takeaways
  • The primary endpoint is NPI-2 assessing hallucinations and delusions.
  • A key secondary endpoint is ADCS-ADL measuring daily function.
  • Regulatory alignment was reached but does not prove drug efficacy.